Oramed Pharmaceuticals Inc.
2 Elza Street
Jerusalem
93706
Tel: 011-972-54-7909058
Fax: 011-972-2-6792336
Website: http://www.oramedpharma.com/
Email: info@oramedpharma.com
324 articles about Oramed Pharmaceuticals Inc.
-
Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company
9/21/2023
Oramed Pharmaceuticals Inc. announced that on September 21, 2023, Oramed and Scilex Holding Company entered into a Securities Purchase Agreement pursuant to which Scilex issued a Senior Secured Promissory Note to Oramed.
-
Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally
8/2/2023
Oramed Pharmaceuticals Inc. announced that it has signed a non-binding term sheet with Hefei Tianhui Biotech Co., Ltd. to establish a joint venture based on Oramed's oral drug delivery technology.
-
Oramed to Present at the 83rd American Diabetes Association Conference
6/20/2023
Oramed Pharmaceuticals Inc. announced today that it has been selected to present an oral abstract presentation at the American Diabetes Association's 83rd Scientific Sessions, taking place between June 23-26, 2023 in San Diego, California.
-
Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit
5/18/2023
Oramed Pharmaceuticals Inc. announced today that Chief Scientific Officer Dr. Miriam Kidron will deliver an in-person presentation at the Novel Therapies for Type 2 Diabetes & Obesity Summit in Boston, MA , on May 31, 2023.
-
Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China
5/15/2023
Oramed Pharmaceuticals Inc. announced today that Hefei Tianhui Biotechnology Co. Ltd. (HTIT), a strategic partner of Oramed, has successfully completed its Phase 3 trials of oral insulin in type 2 diabetes in China under a differentiated study protocol.
-
Oramed Appoints Ben Shapiro to its Board of Directors
5/1/2023
Oramed Pharmaceuticals Inc. announced the appointment of Mr. Benjamin Shapiro to its Board of Directors effective May 1, 2023.
-
Oramed Pharmaceuticals Issues Shareholder Update - February 09, 2023
2/9/2023
Oramed Pharmaceuticals Inc., announced that it continues to conduct a comprehensive analysis of the data from its discontinued Phase 3 oral insulin trials.
-
Oramed, a clinical-stage company developing orally available versions of biologic drugs, reported disappointing news regarding its lead candidate, ORMD-0801.
-
Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes
1/12/2023
Oramed Pharmaceuticals Inc. announced top-line results from its Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes at 26 weeks.
-
Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes - January 4, 2023
1/4/2023
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes."
-
Oramed Letter to Shareholders
12/21/2022
Oramed Pharmaceuticals Inc. today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron.
-
MEDICOX Signs Contract with ORAMED to Distribute Oral Insulin in South Korea
11/18/2022
On 14th, MEDICOX, listed on KOSDAQ, signed an exclusive distribution contract with an oral drug delivery platform developer, ORAMED Pharmaceuticals on the oral insulin license.
-
Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH
11/17/2022
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) today announced additional positive data from its Phase 2 double-blind, fully randomized, placebo-controlled, multicenter clinical trial (ORA-D-N02) to assess the safety and efficacy of its oral insulin candidate (ORMD-0801), to reduce liver fat content in Type 2 Diabetes patients with non-alcoholic steatohepatitis ("NASH").
-
Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea
11/14/2022
Oramed Pharmaceuticals Inc. today announced it has signed an exclusive commercial distribution agreement for the Republic of Korea (formerly South Korea) with Medicox Co., Ltd., an emerging biotech company with an excellent consortium of proven partnerships in the Republic of Korea.
-
Oramed Reports Third Quarter 2022 Financial Results
11/10/2022
Oramed Pharmaceuticals Inc. today reported its financial results for the quarter ended September 30, 2022.
-
Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH
11/9/2022
Oramed Pharmaceuticals Inc. today announced that it will host a data presentation on newly released safety and efficacy data from the Phase 2 trial of its oral insulin candidate (ORMD-0801) to reduce liver fat content in Type 2 Diabetes ("T2D") patients with non-alcoholic steatohepatitis ("NASH") on Thursday, November 17, 2022, at 11:00 a.m. Eastern Standard Time.
-
Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine
10/7/2022
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com) today announced that its subsidiary, Oravax Medical Inc., reported positive preliminary data from its Phase 1 trial of an oral Covid-19 vaccine candidate.
-
New data from Axcella, PepGen, Dystrogen and Galecto are showing promise in challenging diseases, including NASH, Duchenne muscular dystrophy and myelofibrosis.
-
Oramed announced positive mid-stage data that showed its investigational drug ORMD-0801 reduced liver fat content in type 2 diabetes patients who have been diagnosed with NASH.
-
Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate
9/13/2022
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today positive Phase 2 results from its double-blind, fully randomized, placebo-controlled, multicenter trial to assess the safety and efficacy of its oral insulin candidate (ORMD-0801).